Could AstraZeneca be eyeing a significant acquisition? That was the question raised by analysts at RBS, as they highlighted a “persistent $10bn (£6bn) cash pile” at the drug maker.
via telegraph.co.uk
Could AstraZeneca be eyeing a significant acquisition? That was the question raised by analysts at RBS, as they highlighted a “persistent $10bn (£6bn) cash pile” at the drug maker.
No comments:
Post a Comment